Modified Anti-PstS1 Bi-specific antibodies unlock potent protection against tuberculosis
PLOS Pathogens · 27.05.2026 · 22 (5) · e1014133
DOI: 10.1371/journal.ppat.1014133 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 27.05.2026. Verfasst von Akanksha und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gray School of Medical Sciences, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv-Yafo, Israel. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antibodies, Bacterial, Antibodies, Monoclonal, Tuberculosis. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill & Melinda Gates Foundation, European Commission, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
The role of antibodies in the host response against Mycobacterium tuberculosis ( M. tb ) bacteria is still poorly understood. We previously isolated two monoclonal antibodies (mAbs), p4-36 and p4-163, from an M. tb infected donor that target two non-overlapping epitopes on PstS1, a subunit of the M. tb phosphate transporter. Although these antibodies reduced lung bacterial burden in mice (30–40% reduction in CFU), their efficacy remained modest for therapeutic application. Here, we employed a rational antibody engineering approach to further enhance their anti- M. tb potency. Affinity maturation of p4-163 yielded p4-163LR, a variant with superior binding to PstS1 and improved recognition of live, attenuated M. tb . Surprisingly, p4-163LR alone did not confer enhanced protection against virulent M. tb in vivo . However, the generation of a bispecific antibody combining p4-36 and p4-163LR (Bi-S 36/163LR) significantly improved bacterial binding and antibody-dependent cellular phagocytosis (ADCP). Notably, prophylactic administration of Bi-S 36/163LR led to a ~ 1 log reduction in lung bacterial burden compared to control animals treated with isotype control. These findings define a novel, structure-guided strategy to amplify the functional capacity of natural anti- M. tb antibodies and highlight bispecific antibody platforms as promising candidates for host-directed tuberculosis immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gray School of Medical Sciences, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv-Yafo, Israel.
- Division of Experimental Medicine, University of California San Francisco, San Francisco, California, United States of America.
- Department of Biochemistry & Molecular Biology, School of Neurobiology, Biochemistry & Biophysics, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv-Yafo, Israel.
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
ORCID-Profile: Natalia T Freund
Förderung
- Bill & Melinda Gates Foundation
- European Commission
- Bill and Melinda Gates Foundation
- Israel Science Foundation
- United States - Israel Binational Science Foundation
Zitieren
APA
Akanksha, Bouzeyen, R., Watson, A., Wiseglass, G., Sithole, N., Abramovitz, L., Ben-Shalom, N., Rubinstein, R., Javid, B., & Freund, N. T. (2026). Modified Anti-PstS1 Bi-specific antibodies unlock potent protection against tuberculosis. PLOS Pathogens, 22(5), e1014133. https://doi.org/10.1371/journal.ppat.1014133
Vancouver
Akanksha, Bouzeyen R, Watson A, Wiseglass G, Sithole N, Abramovitz L, et al. Modified Anti-PstS1 Bi-specific antibodies unlock potent protection against tuberculosis. PLOS Pathogens. 2026;22(5):e1014133. doi:10.1371/journal.ppat.1014133
BibTeX
@article{Akanksha2026,
author = {Akanksha and Bouzeyen, Rania and Watson, Avia and Wiseglass, Gil and Sithole, Nyaradzai and Abramovitz, Lilach and Ben-Shalom, Noam and Rubinstein, Rotem and Javid, Babak and Freund, Natalia T},
title = {Modified Anti-PstS1 Bi-specific antibodies unlock potent protection against tuberculosis},
journal = {PLOS Pathogens},
year = {2026},
volume = {22},
number = {5},
pages = {e1014133},
doi = {10.1371/journal.ppat.1014133}
}
EUVIMED